Yuki Katsuya

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 13

Top Topics

Combination Therapy

Respiratory Syndrome Coronavirus

Top Venues

International journal of clinical oncology

Cancer biology & medicine

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada, Noboru Yamamoto
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International journal of clinical oncology 29 (4) (2024)
Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada, Noboru Yamamoto
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International journal of clinical oncology 29 (4) (2024)
Yuki Katsuya
Current and future trends in whole genome sequencing in cancer. Cancer biology & medicine 21 (1) (2024)
Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada, Noboru Yamamoto
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International journal of clinical oncology 29 (4) (2024)
Yuki Katsuya
Current and future trends in whole genome sequencing in cancer. Cancer biology & medicine 21 (1) (2024)
Yuki Katsuya
Current and future trends in whole genome sequencing in cancer. Cancer biology & medicine 21 (1) (2024)
Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada, Noboru Yamamoto
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International journal of clinical oncology 29 (4) (2024)
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, Ryoko Seki, Noboru Yamamoto
Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors. Cancer research communications (2024)
Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada, Noboru Yamamoto
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International journal of clinical oncology (2024)
Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada, Noboru Yamamoto
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International journal of clinical oncology 29 (4) (2024)
Yuki Katsuya
Current and future trends in whole genome sequencing in cancer. Cancer biology & medicine 21 (1) (2024)
Tomoyuki Satake, Shunsuke Kondo, Noriko Tanabe, Takaaki Mizuno, Yuki Katsuya, Jun Sato, Takafumi Koyama, Tatsuya Yoshida, Makoto Hirata, Noboru Yamamoto
Pathogenic germline variants in BRCA1/2 and p53 identified by real-world comprehensive cancer genome profiling tests in Asian patients. Cancer research communications (2023)
Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, Shunsuke Kondo, Kan Yonemori, Kohei Shitara, Satoshi Shiono, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Takuya Suzuki, Takao Takase, Shuya Takashima, Kohei Yamaguchi, Taro Semba, Noboru Yamamoto
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. Cancer research communications 3 (7) (2023)